HUM-MOLGEN events: Innovations in Transgenic Technologies

HUM-MOLGEN -> Events -> Meetings and Conferences

June 11, 2001

SMi Conferences, London, England
10th & 11th September 2001

Day One - Monday 10th September 2000

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks
Dr Mark Moore, Chief Scientific Officer, Deltagen

TECHNOLOGY
INTRODUCTION
9.10 Evolution of technology in the biopharma market
 Advances in DNA manipulation techniques.
 Current uses of transgenics
 Improving animal models
 Current DNA insertion techniques
 DNA microinjection
 Retrovirus-mediated transgenesis
 Embryonic stem (ES) cell-mediated gene transfer
 Novel methods of DNA insertion
 Applying transgenics in drug development
Kader Thiam, Senior Scientific Consultant, Head, Immunology Department, genOway

TRANSGENICS: OVERCOMING BARRIERS TO PHARMACEUTICAL RESEARCH
9.40 Case study: Real-time in vivo imaging - technology to monitor bioactivity
 In vivo imaging: visualising the way forward
 More data, better quality
 Widening the bottlenecks in drug discovery
 Applications: how, where and why?
 Predicting the future in pharmaceutical research
Dr Anthony Purchio, Vice President & Chief Science Officer,Xenogen

USING ARTIFICIAL CHROMOSOMES TO PRODUCE NOVEL PROTEIN THERAPEUTICS
10.20 Case study: ACes Technology
 What is ACes technology
 The Chromos Soloution
 Applying ACes for transgenic production
 Outlook- development of protein-based products
Dr Joseph Zendegui, Vice President, Business Development, Chromos Molecular Systems

11.00 Morning Coffee

USING GENE TARGETED ANIMAL MODELS
11.20 Case study: Cephalon
 Overview
 Target selection
 Strategy for Drug Discovery/Target Validation
 Signal Transduction Modulators
 Protease inhibitors
 Neurotrophic factors
Dr Jeffry Vaught, President, Research & Development, Cephalon

ACCELERATED BACKCROSSING / SPEED CONGENICS
12.00 Decreasing the generations, costs and time in congenic transgenic model production
 Directed versus random backcrossing breeding strategies
 Background strain characterization
 Introducing MAX-BAXSM technology
 Case studies and strategy impact
 Adherence to the three R’s Reduce, Refine, Replace
Will Gergits, Managing Partner, Therion International & Charles River Laboratories
12.40 Networking Lunch

NON-VIRAL METHODOLOGY
1.40 Novel application of microinjection and genemodification technologies
 Viral vs non viral vectors
 Advancing gene therapy and functional genomics: Gene-Cell technologies
 Glass needle microinjection technology
 Gene modification technology: gene repair vs. gene compensation
 Applications to transgenic technology
Dr Brian R.Davis, President & Chief Executive Officer, Gene-Cell

TRANSGENICS IN MONOCLONAL ANTIBODY PRODUCTION
2.20 XenoMax TM Technology
 “Magic bullets”; what is the significance of antibodies as a class of therapeutic drugs?
 Human antibodies from immunised XenoMice
 How therapeutic, fully human antibodies will increase the pharmaceutical pipeline
 Application of antibodies to validation of genomics targets
 Improving therapeutics:
 Accelerating the path to the clinic
 Improving the side effect profile
Dr Geoffrey Davis, Chief Scientific Officer, Abgenix

HIGH AFFINITY FULLY HUMAN MONOCLONAL ANTIBODIES
3.00 Introducing the TransChromo MouseTM
 The development of the TransChromo TM technology
 The development of the TC mouse to:
- Carry human immunoglobulin genes producing fully human antibodies
- Generate high affinity, fully human antibodies
- Generate hybridoma clones for the majority of Ig subclasses
 The continuing development of TC Mouse technology
Dr Kazuma Tomizuka, Senior Research Scientist, Kirin Brewery

3.40 Afternoon Tea

ANALYSIS OF GENE FUNCTION AND TARGET VALIDATION
4.00 Using ZFP-transgenic mice
 Zinc finger DNA binding proteins (ZFPs)
 Targeted gene regulation with ZFP transcription factors
 Conditional knockouts with ZFP technology
 Proprietary advantage of ZFP-transgenic models
 Dealing with joint ownership and other collaborative IPR issues
Dr Peter Bluford, Vice President, Business Development, Sangamo Biosciences

USING LENTIVIRUS TRANSFER SYSTEMS
4.30 Applications in drug discovery
 Development of minimal lentiviral vectors
 Smartomics: target discovery focused by gene transfer
 Target validation using LentiVectors
 Application to neurodegenerative and other diseases
 Future directions
Dr Chris Mundy, Head,Gene Discovery, Oxford Biomedica

5.00 Chairman’s Closing Remarks and Close of Day One

Day Two - Tuesday 11th September 2001

8.30 Re-registration and Coffee

9.00 Chairman's Opening Remarks
Geoff Cook Business Development Manager, PPL Therapeutics

APPLICATIONS

GENE EXPRESSION IN SKELETAL MUSCLE
9.10 Evaluating therapeutic strategies for inherited and acquired diseases
 A platform for local or systemic distribution of protein products
 Functional assays following germ line and somatic gene transfer
 Improvements in somatic gene transfer technology
 Barriers to clinical application
 Combining germ-line and somatic gene transfer to model gene therapy
 Future prospects
Dr Dominic Wells, Reader in Transgenic Biology, Imperial College School of Medicine

INNOVATIONS IN ONCOLOGY
9.40 Applications of transgenic models
 Recent developments utilising transgenics in cancer research
 From the lab to the real world, the market opportunities for products
 Overcoming the challenges of implementing cancer technology
 What the future holds for cancer research using transgenics
 Future commercialisation of this technology
Marlise Potelle, Director, Commercial Development, Genzyme Transgenics

LINKING RESEARCH WITH THERAPY IN CARDIOVASCULAR DISEASE
10.20 Applications of transgenic models
 Recent developments in the cardiovascular market using transgenics
 Advantages of using transgenics to develop a CV therapeutic
 Transgenic animal models of atherosclerosis
 Interpretation of drug intervention transgenic studies
 Future developments
Dr Ian Graham, Senior Research Fellow, Division of Biochemistry, Royal Holloway, University of London

11.0 Morning Coffee

NEURODEGENERATIVE DISEASE MODELS
11.20 Applications of transgenic animals
 An overview of animal models in Alzheimer’s Disease (AD)
 What is the impact of gene disruption and transgenic technology in neurodegenerative research
 Amyloid precursor protein and presenilin knockouts
 Transgenes linked to familial early onset AD
 Development of new strains relevant to Alzheimer's Disease Conditional transgenics
Dr Thomas Rosahl, Research Fellow, Merck Sharp & Dohme

XENOTRANSPLANTATION: IS THERE A FUTURE?
12.00 Using multiple approaches to pave the way
 The issues and need for xenotransplantation
 Recent developments utilizing transgenics and nuclear transfer in xenotransplantation
 Overcoming the challenges of xenotransplantation technology.
 Fighting the ethical battle- strategies for success/ is there really a choice?
 What the future holds for xenotransplantation / commercialisation of this technology.
Dr Julia Greenstein, President & Chief Executive Officer, Immerge Biotransplant

12.40 Networking Lunch

VIRUS TRANSMISSION
1.40 Estimating the risk from the use of transgenic technologies
 Animal viruses and Zoonosis
 Safety testing strategies and how they are evolving
 Retroviruses both endogenous and exogenous
 Coping with the new emerging virus danger
Dr Daniel Galbraith, Associate Director, Virology, Q-One Biotech

PRODUCTION

OLD MACDONALD HAD A BIOTECH COMPANY
2.20 Introduction to a new kind of “pharming”
 Taking your “pharm” produce to market
 Novel methods for obtaining therapeutics
 Producing high output levels without endangering host
 Embryo viability
 Health, Safety and Pharmacovigilance
Dr Frank Pieper, Vice President, Research & Technology, The Pharming Group

INTEGRATING DISCOVERY AND PRODUCTION OF NATURAL SOURCE THERAPEUTIC BIOLOGICS
3.00 Case study: from milk to man
 To Genie with love: a personal story with the pioneer pig
 Transgenic animal productivity
 US market for “made in transgenic bioreactor” pharmaceuticals
 Past and present down-stream transgenic milk processing: benefits and limitations
 Novel process for removal of caseins from milk of transgenic animals
 Strategies for scale-up:integrating BioSante process into the existing stream
 Market application and exploitation
Dr Tulin Morcol, Senior Scientist, BioSante Pharmaceuticals

3.40 Afternoon Tea

TRANSGENIC CHICKEN BASED PROTEIN PRODUCTION
4.00 Case study: Laying the golden eggs
 Biologics production: opportunities for the transgenic chicken
 Advantages and current limitations of protein production from eggs
 Progress of avian transgenic technology
 From egg to drug: processing egg proteins
 Strategic challenges: regulatory acceptance and public perception
 Golden eggs: future use for commercial production
Anthony Cruz, Vice President, Corporate Development & Strategic Planning, Avigenics

RECOMBINANT PROTEINS FROM TRANSGENIC PLANTS
4.30 Plant-based expression systems for the manufacture of therapeutic recombinant
proteins
 Opportunities for large-scale protein production in agricultural systems
 Transforming plants to produce antibodies and vaccines
 Seed-based vs tissue-based systems
 Manufacturing issues: producing therapeutic proteins using plant technology
 The emerging regulatory environment
 The future use of plant systems
Dr Manfred Theisen, Scientific Director & Chief Scientific Officer, Meristem Therapeutics

5.00 Chairman's Closing Remarks and Close of Conference

Organized by:

SARAH SANDS

Invited Speakers:

Dr Thomas Rosahl, Research Fellow, Merck Sharp & Dohme
Marlise Potelle, Director, Commercial Development, Genzyme Transgenics Corporation
Dr Chris Mundy, Head, Gene Discovery, Oxford Biomedica
Dr Anthony Purchio, Vice President & Chief Science Officer, Xenogen
Dr Will Gergits, Managing Partner, Therion International & Charles River Laboratories
Dr Frank Pieper, Vice President, Research & Technology,The Pharming Group
Dr Joseph Zendegui, Vice President, Business Development, Chromos Molecular Systems
Dr Brian Davis, President & Chief Executive Officer, Gene-Cell
Anthony Cruz, Vice President, Corporate Development & Strategic Planning, Avigenics
Dr Kader Thiam, Senior Scientific Consultant & Head, Immunology Department, genOway
Dr Manfred Theisen, Scientific Director, Chief Scientific Officer, Meristem Therapeutics
Dr Peter Bluford, Vice President, Business Development, Sangamo Biosciences
Dr Geoffrey Davis, Chief Scientific Officer, Abgenix
Dr Kazuma Tomizuka, Senior Research Scientist, Kirin Brewery
Dr Julia Greenstein, President & Chief Executive Officer, Immerge Biotransplant
Dr Ian Graham, Senior Research Fellow, Division of Biochemistry, Royal Holloway University of London
Dr. Dominic Wells, Reader inTransgenic Biology, Imperial College School of Medicine
Dr Daniel Galbraith, Associate Director, Virology, Q-One Biotech
Dr Jeffry Vaught, President, Research & Development, Cephalon
Dr Tulin Morcol, Senior Scientist, BioSante Pharmaceuticals

Chaired by:
Dr Mark Moore, Chief Scientific Officer, Deltagen
Geoff Cook Business Development Manager, PPL Therapeutics

Deadline for Abstracts:

Closed

Registration:

£1099+VAT

E-mail:

ssands@smi-online.co.uk

Posted by:

Sarah Sands

Host:

213.38.112.46